Skip to content

APAD2: Effects of Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics

Effects Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics Persons

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00234273
Enrollment
10
Registered
2005-10-06
Start date
2004-11-30
Completion date
2008-06-30
Last updated
2013-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NIDDM

Keywords

Adapted Physical Activity, Quality of life, cardiovascular risk, teaching, Directly Observed Therapy, Physical activity

Brief summary

The principal objective is to assess and analyze the effects of a six month programme in Adapted Physical Activity (APA) on physical activity, compliance, and insulin resistance among type 2 diabetics.

Detailed description

Clinical trial with direct individual profit. Study phase 2. Study center: University Hospital Grenoble Principal investigator: Pr. Serge HALIMI Sponsor: University Hospital Grenoble The principal objective is to assess and analyze the effects of a six month programme in Adapted Physical Activity (APA) on physical activity, compliance, and insulin resistance among type 2 diabetics. Secondary objectives are to assess and analyze the effects of a six month programme in APA of: * arterial tension * weight, body composition and abdominal perimeter * quality of life * treatment dosage * number of hospitalisation thick a diabetes complication acute for one year and for each patient Compare two exercise's intensity: first lactate threshold (SL1) and crossover (PCGL). Inclusion criteria: * type 2 diabetics * age \> 40 years * first education in Education Diabetics Department of University Hospital Grenoble * sedentary patients * HbA1c \> 7%- * BMI \> 25 * to be affiliate disease assurance * to give consent written and inform Judgment criteria for physical activity compliance: * leisure time physical activity: Modifiable Activity Questionnaire * training note-book Judgment criteria for resistance insulin: * Crossover (PCGL) * HOMA and FIRI index * HbA1c Programme test: Rehabilitation programme in Adapted Physical Activity (APA) Programme test period: 6 months Study total period: 28 months Study period for each patient: 18 months Safety criteria: clinical compendium undesirable events

Interventions

PROCEDURERehabilitation programme in Adapted Physical Activity (APA)
BEHAVIORALTherapeutic education primarily focused on dietary

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Type 2 diabetics * Age \> 40 * First education in the Education Diabetics Department of the University Hospital Grenoble * Sedentary patients * Hemoglobin A1c (HbA1c) \> 7% * Body mass index (BMI) \> 25 * To be affiliated with disease assurance * To give written and informed consent

Exclusion criteria

* Foot sore \< six months * Renal disease - proteinuria stage * Contraindication for exercise * VO2 max \> 120% Wassermann standard * Coronary pathology non-stabilization * Arteriopathy stage 2 non-compensation * Osteo-articular crippling problem * Geographically distant

Design outcomes

Primary

MeasureTime frameDescription
Increase physical activity compliance long-term6 months after the beginning of the programModifiable Activity Questionnaire (MAQ
Lessen insulin resistance6 months after the beginning of the programHOMA (Homeo-stasis model assessment), HbA1c, PCGL

Secondary

MeasureTime frameDescription
Improve the quality of life6 months after the beginning of the programShort Form-36 Health Survey Questionnary (SF-36)
Improve the arterial tension6 months after the beginning of the programarterial tension
Lessen the weight6 months after the beginning of the programweight

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026